HRMY Stock Analysis: Buy, Sell, or Hold?
HRMY - Harmony Biosciences Holdings, Inc. Common Stock
$36.52
-0.34 (-0.92%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 24, 2026
22d
Get Alerted When HRMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HRMY shows positive signals but monitor for confirmation. Market pricing in 0.8% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: HRMY shows positive signals but monitor for confirmation. Market pricing in 0.8% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$69.15
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$42.94
14.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HRMY is currently trading at $36.52, which is considered slightly low relative to its 30-day fair value range of $36.39 to $37.97. The stock's valuation (Forward PE: 6.8) is in line with its historical norms (6.6). At these levels, the market is pricing in 0.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HRMY is in a strong uptrend. Immediate support is located at $35.16, while resistance sits at $37.98.
Market Sentiment: HRMY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $46.45 (+27.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HRMY is in a strong uptrend. Immediate support is located at $35.16, while resistance sits at $37.98.
Market Sentiment: HRMY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $46.45 (+27.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$36.39 -
$37.97
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 27.2% below Wall St target ($46.45)
- NEUTRAL: Market pricing in 0.8% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$36.39 -
$37.97
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$1.84
(5.0%)
Support & Resistance Levels
Support Level
$35.16
Resistance Level
$37.98
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
6.79
Wall Street Target
$46.45
(+27.2%)
Revenue Growth (YoY)
28.7%
Earnings Growth (YoY)
10.1%
Profit Margin
22.5%
Valuation Premium vs History
+0.8% premium
PE vs Historical
6.8 vs 6.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.8%
(market-implied from PE analysis)
1-Year Target
$36.81
(+1%)
2-Year Target
$37.11
(+2%)
3-Year Target
$37.40
(+2%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$36.37
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 32.8%)
$281.17
(+670%)
Base:
(SPY PE: 6.8, Growth: 32.8%)
$85.58
(+134%)
Bear:
(PE: 5.8, Growth: 32.8%)
$72.74
(+99%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 11.62 | Current EPS (TTM): $3.17
Bull Case
$68.78
(+88%)
Analyst growth 69.7%, PE expands to 12.8
Base Case
$62.53
(+71%)
Market implied 69.7%, PE stable at 11.6
Bear Case
$25.05
(-31%)
Severe decline -20.0%, PE contracts to 9.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 31, 2026 9:52 PM ET
Data refreshes hourly during market hours. Next update: 10:52 PM
Data refreshes hourly during market hours. Next update: 10:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HRMY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$141 | 59 HOLD |
Advanced HRMY Option Strategies
Professional options setups generated by AI based on today's HRMY price and gamma walls.
